CMPX

Compass Therapeutics, Inc. [CMPX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CMPX Stock Summary

Top 10 Correlated ETFs

CMPX

Top 10 Correlated Stocks

CMPX

In the News

CMPX Financial details

Company Rating
-
Market Cap
206.53M
Income
-37.51M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
21 Mar 2024
P/E
-6.56
Forward P/E
-
PEG
0.86
P/S
-
P/B
1.54
P/C
-
P/FCF
-6.31
Quick Ratio
17.94
Current Ratio
18.26
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.31
EPS next Y
-
EPS next Q
-
EPS this Y
-73.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-12.13%
-
-
-
-
SMA20
36.4%
SMA50
114.47%
SMA100
99.42%
Inst Own
-
Inst Trans
-
ROA
-22%
ROE
-22%
ROC
-0.3%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.15-3.62
52W High
-2.67%
52W Low
+192%
RSI
48.3
Rel Volume
2.85
Avg Volume
395.31K
Volume
1.13M
Perf Week
-20%
Perf Month
104.2%
Perf Quarter
145.38%
Perf Half Y
145.38%
-
-
-
-
Beta
0.571
-
-
Volatility
0.25%, 0.55%
Prev Close
-5.19%
Price
2.92
Change
-12.57%

Something similar

Top by Market Cap
BRYN.DE
ABEA.DE
APC.DE
AMZN
1YD.DE
Top Correlated ETFs
ZMBS.TO
DAT
WFH
LRNZ
META
Top Correlated Stocks
DSP
SBFG
FXNC
MNPR
JAMF
Similar Market Cap
CNIC.L
MPA
GWOX
3301.HK
TWM.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 395.31K
  • Market Capitalization 206.53M
  • Employee 26
  • CEO Dr. Vered Bisker-Leib M.D., MBA, Ph.D.
  • Headquarters Boston,MA,US
  • IPO Date 2021-04-05
  • Website https://www.compasstherapeutics.com

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.